Reflections and copy/paste from today announcement
Post# of 721
(Total Views: 342)
Posted On: 12/01/2020 5:30:59 PM
Reflections and copy/paste from today announcement. Drugs like darunavir and efavirenz are mainly used for treatment of HIV/AIDS, although their bioavailability alone in oral form is low at 37% and 45%, respectively. If confirmed through additional expanded testing,
DehydraTECH could, in theory, improve this bioavailability rate to as high as 64% (i.e., darunavir 37% x 154% = 57%; or efavirenz 45% x 142% = 64%) which could greatly enhance outcomes thus warranting continued investigation.
janssen pharmaceuticals ; is the largest manufacturer of these drugs - let`s hope they are the pharma partner I have speculated about; https://www.janssen.com/
Finally, both of the drugs are so called "essential drugs" on the WHO list - meaning any improvement of effectivnes would be welcome by many supporters, with this comes also an easier path to finance the testing, develop the end-product and fast-track it to approval (updated) since FDA has the drug already cleared as it stands today.
Read More: https://investorshangout.com/post/view?id=597...z6fPgBxBPC
DehydraTECH could, in theory, improve this bioavailability rate to as high as 64% (i.e., darunavir 37% x 154% = 57%; or efavirenz 45% x 142% = 64%) which could greatly enhance outcomes thus warranting continued investigation.
janssen pharmaceuticals ; is the largest manufacturer of these drugs - let`s hope they are the pharma partner I have speculated about; https://www.janssen.com/
Finally, both of the drugs are so called "essential drugs" on the WHO list - meaning any improvement of effectivnes would be welcome by many supporters, with this comes also an easier path to finance the testing, develop the end-product and fast-track it to approval (updated) since FDA has the drug already cleared as it stands today.
Read More: https://investorshangout.com/post/view?id=597...z6fPgBxBPC
(1)
(0)Lexaria Bioscience Corp. (LXRPD) Stock Research Links
Robert
Scroll down for more posts ▼